United Patients Group points to growing evidence that cannabis extracts kill cancer cells, and calls on powerful individuals to fund clinical trials of this potential cancer cure and for state and federal regulatory agencies to help facilitate such research.
United Patients Group announced a call for research into the therapeutic effects of cannabis extracts in cancer, given the growing and clear evidence indicating cannabis has anticancer effects in humans. They are urging known philanthropists and individuals interested in cancer breakthroughs to help fund clinical trials of the cancer-destroying power of cannabis extracts.
“A number of recent studies have shown that medical cannabis does much more than improve patient’s symptoms—it may, in fact, be a substantial anticancer treatment itself,” said John Malanca, founder and owner of United Patients Group, a trusted news source and advocate for medical cannabis patients. “Yet the federal government ignores these studies and refuses to fund research in this area (even though they hold a patent on cannabis as a therapeutic treatment – US Patent #6630507.
“Philanthropic individuals, we are in need of your help in fast-tracking this research. The government refuses to see what’s already evident: that cannabis extracts can kill cancer cells. So we’re asking people like Sir Richard Branson, Sara Blakely, John Paul DeJoria, Ted Turner, George Lucas, Bill Gates, Michael Ashcroft, Dan and Jennifer Gilbert, Larry Ellison, and other powerful advocates of human health to fund rigorous scientific research into these compounds that could potentially save millions of lives,” he urged.
A recent blog post, entitled, “Cannabis Extract Treatment for Terminal Acute Lymphoblastic Leukemia” on UnitedPatientsGroup.com collects some of the groundbreaking studies that have demonstrated that certain cannabis compounds damage and kill cancer cells. These studies include the following:
- A 2013 article in Case Reports in Oncology profiled the case of a 14-year-old girl with lymphoblastic leukemia. Traditional treatments had failed to help her, so she began taking cannabis oil. Her leukemic blast cell count plunged from 374,000 to 300 in just over a month. Unfortunately, the patient passed away from side effects from prior chemotherapy and radiation treatments.
- A 2011 study published in Child’s Nervous System, the official journal of the International Society for Pediatric Neurosurgery, found an association between cannabis inhalation and brain-tumor regression in two adolescent patients. The patients both had residual tumors from pilocytic astrocytoma, and inhaling cannabis regularly resulted in a “clear regression” of their tumors over the course of three years, with no other treatment concurrent.
- Many animal studies have shown that the cannabinoid THC, a primary medicinal compound in cannabis, inhibits and induces cell death in cancers including brain cancer, prostate cancer, colorectal cancer, pancreatic cancer, and leukemia.
- Another cannabinoid, CBD, has also been shown in animal studies to kill multiple kinds of cancer cells, and studies suggest that multiple cannabinoids act together to create a synergistic cancer-killing effect.
Anecdotal evidence of the incredible healing powers of cannabis is compelling. Dr. Stanley Rutner went from ten days to live to “No Evidence of Cancer” when he began taking cannabis oil in a daily regimen.
Cash Hyde, a four-year-old with brain cancer, was brought back from the brink of death several times by cannabis oil, but he ultimately succumbed when his family was unable to obtain enough oil to keep his treatment going.
Hundreds of additional cases have demonstrated similar results.
This overwhelming evidence of the power of cannabis to treat cancer has lead doctors to call for further research. Dr. Yadenver Singh and Dr. Mansoor Foroughi, authors of the referenced studies in Case Reports in Oncology and Child’s Nervous System, respectively, and the latter a recipient of the 2013 Braakman award from the European Association of Neurological Surgeons, each concluded that clinical trials should be undertaken.
Dr. Raphael Mechoulam, the iconic Israeli researcher who discovered tetrahydrocannabinol (THC) in 1964, and whose lab discovered the first endocannabinoid anandamide in 1992, strongly suggests that such trials “should be planned and undertaken as soon as possible.”
Dr. Sunil Aggarwal, a 2014–15 Clinical Fellow in Hospice and Palliative Medicine at the National Institutes of Health Clinical Center, joins this call for research.
“For the good of the human race, we ask these powerful individuals, who have shown their dedication to easing human suffering, to step up and help fund these clinical trials and for government to facilitate this important research,” implored Malanca.
For more on this topic, please contact United Patients Group at 415-524-8099 or Dr. Sunil Aggarwal at email@example.com.